Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Why Regeneron (REGN) Stock Is Trading Up Today

January 07, 2026 at 11:20 AM EST

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

REGN Cover Image

What Happened?

Shares of biotech company Regeneron (NASDAQ: REGN) jumped 2.9% in the morning session after Bank of America Securities upgraded its rating on the company's stock from 'Underperform' to 'Buy' and significantly raised its price target. The firm's analyst, Tim Anderson, lifted the price target to $860.00 from a previous $627.00. This move signaled growing confidence in Regeneron's market prospects. Adding to the positive sentiment, Citi also raised its price target on the shares to $900 from $700 while keeping its 'Buy' rating. Reflecting the bullish analyst actions, the stock reached a new 52-week high, underscoring the positive momentum.

After the initial pop the shares cooled down to $798.51, up 2.8% from previous close.

Is now the time to buy Regeneron? Access our full analysis report here.

What Is The Market Telling Us

Regeneron’s shares are somewhat volatile and have had 11 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The biggest move we wrote about over the last year was 7 months ago when the stock dropped 19% on the news that the company announced mixed results from its Phase 3 trials for itepekimab, an experimental drug for Chronic Obstructive Pulmonary Disease (COPD). While one trial met its primary endpoint, the other missed, raising concerns about the drug's future and delaying its potential market entry. This setback, likely spooked investors and contributed to the significant decline.

Regeneron is up 2.9% since the beginning of the year, and at $798.51 per share, has set a new 52-week high. Investors who bought $1,000 worth of Regeneron’s shares 5 years ago would now be looking at an investment worth $1,659.

The 1999 book Gorilla Game predicted Microsoft and Apple would dominate tech before it happened. Its thesis? Identify the platform winners early. Today, enterprise software companies embedding generative AI are becoming the new gorillas. Click here for access to our special report that reveals one profitable leader already riding this wave.

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Symbol

Price

Change (%)

AMZN

274.48

+2.22 (0.82%)

AAPL

313.33

+0.92 (0.29%)

AMD

483.36

-5.92 (-1.21%)

BAC

63.17

+0.17 (0.27%)

GOOG

353.47

-3.15 (-0.88%)